LGND:NASDAQ
Ligand Pharmaceuticals Inc
$288.83
arrow_upward
+1.13%(+3.23) 1D
$288.83
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 8, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LGND...
Open
$285.05
High
$289.28
Low
$278.40
Mkt. cap
5.76B
Avg. vol.
237.24K
Volume
216.42K
P/E ratio
30.72
52-wk high
$326.63
52-wk low
$161.82
EPS
$9.40
Beta
1.03
Shares outstanding
19.94M
No. of employees
47
Open
$285.05
High
$289.28
Low
$278.40
Mkt. cap
5.76B
Avg. vol.
237.24K
Volume
216.42K
P/E ratio
30.72
52-wk high
$326.63
52-wk low
$161.82
EPS
$9.40
Beta
1.03
Shares outstanding
19.94M
No. of employees
47
Profile
Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Notable products from which Ligand receives royalties include the multiple myeloma treatments Kyprolis and Evomela, the kidney disease therapy Filspari, and the pneumococcal vaccine Vaxneuvance. The company also owns the drug development technology platform Captisol.
The company was founded in 1987 as Progenx by venture capitalist Brook Byers; it was renamed Ligand Pharmaceuticals in 1989 and went public in 1992. Following an accounting scandal that led to its delisting from the Nasdaq stock exchange in 2005, the company underwent a major restructuring. Under former CEO John Higgins, who took over in 2007, Ligand shifted its focus from drug development to its current business model of generating revenue from royalties and licensing payments.
Ligand has grown its portfolio primarily through acquisitions, including Pharmacopeia in 2008, CyDex Pharmaceuticals in 2011, and Pfenex in 2020. Wikipedia
About Ligand Pharmaceuticals Inc
CEO-
Employees47
FoundedSep 1987
HeadquartersJupiter, Florida, United States
SectorPharmaceutical industry
Websiteligand.com